DANYELZA (naxitamab-gqgk) for the Treatment of Neuroblastoma

Image 2-DANYELZA (naxitamab-gqgk)
Naxitamab is a new generation monoclonal antibody (mAb) that targets GD2. Credit: Y-mAbs Therapeutics, Inc.